| Date Filed | Type | Description |
| 02/14/2017 |
SC 13G/A
| Camber Capital Management LLC reports a 0% stake in EPIRUS Pharmaceuticals, Inc. |
| 09/26/2016 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 08/01/2016 |
8-K
| Quarterly results |
| 07/25/2016 |
8-K
| Form 8-K - Current report |
| 07/11/2016 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/11/2016 |
SC 13G/A
| FMR LLC reports a 0% stake in EPIRUS BIOPHARMACEUTICALS INC |
| 07/08/2016 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/01/2016 |
8-K
| Form 8-K - Current report |
| 06/14/2016 |
8-K
| Form 8-K - Current report |
| 05/31/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/31/2016 |
4
| Wyand Michael (President and COO) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Granted 280,000 restricted stock units
@ $0 |
|
| 05/31/2016 |
4
| Aurentz Vincent (Chief Business Officer) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Granted 230,000 restricted stock units
@ $0 |
|
| 05/31/2016 |
4
| Ticktin Robert (General Counsel) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Granted 230,000 restricted stock units
@ $0 |
|
| 05/10/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 05/09/2016 |
8-K
| Form 8-K - Current report |
| 04/29/2016 |
10-K/A
| Annual Report for the period ended December 31, 2015 [amend] |
| 03/29/2016 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans |
| 03/28/2016 |
10-K
| Annual Report for the period ended December 31, 2015 |
| 03/15/2016 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| 03/15/2016 |
8-K
| Form 8-K - Current report |
| 03/11/2016 |
4/A
| Wyand Michael (Chief Technical Officer) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Exercised 1,044 shares
@ $0
Exercised 2,608 shares
@ $0
Paid exercise price by delivering 1,378 shares
@ $2.8, valued at
$3.9k
|
|
| 03/01/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 03/01/2016 |
4
| Shea Thomas A. (CFO) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,554 shares
@ $2.8, valued at
$4.4k
Exercised 1,044 restricted stock units
@ $0
Exercised 3,073 restricted stock units
@ $0 |
|
| 03/01/2016 |
4
| Munshi Amit (CEO) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 4,305 shares
@ $2.8, valued at
$12.1k
Exercised 1,519 restricted stock units
@ $0
Exercised 9,887 restricted stock units
@ $0 |
|
| 03/01/2016 |
4
| Wyand Michael (Chief Technical Officer) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Paid exercise price by delivering 1,379 shares
@ $2.8, valued at
$3.9k
Exercised 1,044 restricted stock units
@ $0
Exercised 2,608 restricted stock units
@ $0 |
|
| 03/01/2016 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 02/29/2016 |
8-K
| Form 8-K - Current report |
| 02/09/2016 |
8-K
| Form 8-K - Current report |
| 02/05/2016 |
SC 13G/A
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] |
| 12/22/2015 |
4
| Ticktin Robert (General Counsel) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Bought 3,000 shares
@ $3.7205, valued at
$11.2k
|
|
| 12/21/2015 |
4
| Vincent Aurentz (Chief Business Officer) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Bought 2,200 shares
@ $3.43, valued at
$7.5k
|
|
| 12/17/2015 |
4
| Munshi Amit (CEO) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Bought 8,270 shares
@ $2.8, valued at
$23.2k
|
|
| 12/16/2015 |
4
| Munshi Amit (CEO) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Bought 8,069 shares
@ $2.87, valued at
$23.2k
|
|
| 12/11/2015 |
4
| Vincent Aurentz (Chief Business Officer) has filed a Form 4 on EPIRUS Biopharmaceuticals, Inc.|
Txns:
| Bought 2,800 shares
@ $3.85, valued at
$10.8k
|
|
|